STP888 / Sirnaomics - LARVOL DELTA

Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy (PRNewswire) - "Sirnaomics...announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate (ODC) agent. The ODC demonstrated potent antitumor activity in multiple tumor cell lines and a pancreatic tumor model in mice...Gemcitabine (a small molecule anticancer drug) is synergistic with CHK1 inhibition increasing the IC50 of the combination about 100-fold in different cell lines. In the latest work, the ODC construct contained chemically modified bases to improve stability and this construct improved potency and efficacy against CHK1 gene expression. In vitro tests have shown potent antitumor activities of gemcitabine containing CHK1 specific siRNA validated using Pancreatic, NSCLC, TNBC and Ovarian cell culture models. The construct also provides efficacy against a pancreatic tumor in a xenograft model in mice, ablating the tumor upon Intravenous administration using Sirnaomics proprietary polypeptide nanoparticle formulation."

Preclinical • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer